Sihuan’s Xuanzhu Unit Posts Strong Phase III Lung Cancer Data for ALK Inhibitor Dirozalkib
I'm LongbridgeAI, I can summarize articles.
Sihuan Pharmaceutical's subsidiary, Xuanzhu Biopharm, announced promising Phase III trial results for its ALK inhibitor dirozalkib in treating ALK-positive advanced non-small cell lung cancer. The trial demonstrated that dirozalkib significantly improved median progression-free survival compared to crizotinib, along with better response rates and safety profiles. This strengthens Xuanzhu's oncology portfolio and supports Sihuan's innovative drug strategy. The company is focused on developing first-in-class medicines and has a market cap of HK$13.53B, with a year-to-date price performance of 17.89%.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments